Precigen Inc - Asset Resilience Ratio
Precigen Inc (PGEN) has an Asset Resilience Ratio of 43.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Precigen Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Precigen Inc's Asset Resilience Ratio has changed over time. See PGEN net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Precigen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PGEN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.62 Million | 43.18% |
| Total Liquid Assets | $67.62 Million | 43.18% |
Asset Resilience Insights
- Very High Liquidity: Precigen Inc maintains exceptional liquid asset reserves at 43.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Precigen Inc Industry Peers by Asset Resilience Ratio
Compare Precigen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Precigen Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Precigen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.18% | $67.62 Million | $156.62 Million | -3.90pp |
| 2024-12-31 | 47.08% | $68.39 Million | $145.27 Million | +10.48pp |
| 2023-12-31 | 36.60% | $55.28 Million | $151.04 Million | +12.94pp |
| 2022-12-31 | 23.66% | $51.09 Million | $215.98 Million | +3.58pp |
| 2021-12-31 | 20.07% | $72.24 Million | $359.86 Million | +4.71pp |
| 2020-12-31 | 15.36% | $48.33 Million | $314.59 Million | +13.33pp |
| 2019-12-31 | 2.03% | $9.26 Million | $455.76 Million | -14.73pp |
| 2018-12-31 | 16.77% | $120.07 Million | $716.18 Million | +15.40pp |
| 2017-12-31 | 1.36% | $11.56 Million | $846.85 Million | -17.03pp |
| 2016-12-31 | 18.40% | $174.60 Million | $949.07 Million | +7.96pp |
| 2015-12-31 | 10.44% | $102.53 Million | $982.05 Million | -4.92pp |
| 2014-12-31 | 15.36% | $88.50 Million | $576.27 Million | -11.90pp |
| 2013-12-31 | 27.26% | $127.98 Million | $469.47 Million | +27.09pp |
| 2012-12-31 | 0.17% | $260.00K | $151.65 Million | -0.05pp |
| 2011-12-31 | 0.22% | $258.00K | $114.83 Million | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more